lung adenocarcinoma
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
Lung Cancer Progression, Prognostic Features Investigated in Proteogenomic Studies
Two independent research teams turned to proteogenomics to parse out the transition from pre-invasive to invasive lung adenocarcinoma and to assess small cell lung cancer.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Intra-Tumor Heterogeneity Patterns Correlate With Survival in Lung Cancer Patients
The researchers uncovered two distinct spatial patterns within lung adenocarcinoma using both proteomic and genomic approaches.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.